NCT06208488 - A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants | Biotech Hunter

Enrollment

175

Participants

Timeline

Start Date

November 22, 2023

Primary Completion Date

September 17, 2024

Study Completion Date

September 28, 2024

Conditions

Healthy Adult Participants

Interventions

DRUG

Gefurulimab PFS-SD

Participants will receive a single 600 mg dose of Gefurulimab PFS-SD subcutaneously (SC) on Day 1.

DRUG

Gefurulimab AI

Participants will receive a single 600 mg dose of Gefurulimab AI subcutaneously (SC) on Day 1.

Trial Locations (2)

Research Site, Toronto

Research Site, Laval